WEST CHESTER, PA — Pathways Neuro Pharma, Inc. has announced a strategic partnership with Dragonfly 44 Capital, a move set to bolster the company’s financial and strategic capabilities. The agreement, effective immediately, tasks Dragonfly 44 with providing comprehensive advisory and investment banking services to aid Pathways in reaching its strategic objectives.
This engagement is timely, following significant advancements in Pathways’ AAV6.2FF gene therapy platform. These developments include addressing key intellectual property issues and strengthening its patent portfolio, thereby reinforcing Pathways’ leadership in gene therapy innovation. Dragonfly 44’s role will be crucial in capital raising and securing strategic partnerships to advance Pathways’ development pipeline, which focuses on therapies for alcohol use disorder (AUD) and depression.
Pathways is pioneering a gene therapy approach to depression treatment, aiming to reduce side effects typical of current therapies, thus offering patients a safer, more effective alternative.
Anthony Mack, CEO of Pathways Neuro Pharma, emphasized the importance of this engagement: “The engagement of Dragonfly 44 comes at a time when we have successfully bolstered our patent portfolio, adding further value to our innovative gene therapies. Their expertise will be crucial in helping us secure the resources and partnerships necessary to bring our therapies to patients and meet unmet medical needs in conditions like AUD and depression.”
Dragonfly 44 will be instrumental in evaluating and pursuing a range of financing options, including equity, debt, and hybrid capital avenues. This partnership aims to strengthen Pathways’ financial capabilities as it continues to develop gene therapies targeting central nervous system disorders, focusing on minimizing side effects and enhancing patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.